Join Dr. Mark Kirchhof Oct 18, 8pm ET for virtual review of “Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches” (Blauvelt et al, Br J Dermatol, Jun 2018).

Please join Dr. Mark Kirchhof for WEBINAR 4 of 2018 to be held Thursday, October 18 at 8pm EST, focused on the recent article in the British Journal of Dermatology by Blauvelt et al:

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

NOTE: If you would like a full-text copy of the article above, please contact paul.abbass@legitimed.com

For webinar access details, see calendar invitation.

If you have any comments or questions, please contact:

Paul Abbass
LEGITIMED INC.
paul.abbass@legitimed.com